Diabete Mellitus Clinical Trial
Official title:
Risk Factors for Acute Kidney Injury in Diabetic Patients
Verified date | November 2021 |
Source | Assiut University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
incidence of AKI in diabetic patients seems to be influenced by multiple risk Factors like severe infections, elderly, poor diabetic control, previous AKI, chronic kidney disease and drugs like SGLT2-I increase risk of AKI in diabetic patients.
Status | Not yet recruiting |
Enrollment | 400 |
Est. completion date | December 30, 2023 |
Est. primary completion date | December 30, 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Inclusion criteria for the cases : 200 Diabetic patients of 18 year and older (either type 1or 2) presented by AKI based on KIDIGO Definition & Staging. KDIGO definition of AKI: Increase in serum creatinine by =0.3 mg/dL (=26.5 µmol/L) within 48 h, or Increase in serum creatinine to =1.5 times baseline that is known or presumed to have occurred within the prior 7 days, or Urine volume <0.5 mL/kg/h for 6 h. KDIGO staging of AKI: (1) stage 1: Serum creatinine 1.5-1.9 × baseline or =0.3 mg/dL (=26.5 µmol/L) increase / Urine output <0.5 mL/kg/h for 6-12 h (2) stage 2; Serum creatinine 2.0-2.9 × baseline / Urine output <0.5 mL/kg/h for =12 h (3) stage 3: Serum creatinine 3.0 × baseline, increase in serum creatinine to =4.0 mg/dL (=353.6 µmol/L), initiation of renal replacement therapy, or, in patients <18 years, decrease in eGFR to <35 mL/min per 1.73 m2 / Urine output <0.3 mL/kg/h for =24 h or anuria for =12 h . Inclusion criteria for matched controls 200 Diabetic patients of 18 year and older with no AKI (either type 1or 2) Exclusion Criteria: Exclusion criteria for cases and controls: 1. Non-Diabetic patients with AKI 2. Diabetic patients with: - HBS Ag, HCV, HIV - Active Lupus - Active Malignancy - Acute or Chronic Liver Disease - Acute poisoning |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Assiut University |
American Diabetes Association. (2) Classification and diagnosis of diabetes. Diabetes Care. 2015 Jan;38 Suppl:S8-S16. doi: 10.2337/dc15-S005. Review. — View Citation
Aziz Z, Absetz P, Oldroyd J, Pronk NP, Oldenburg B. A systematic review of real-world diabetes prevention programs: learnings from the last 15 years. Implement Sci. 2015 Dec 15;10:172. doi: 10.1186/s13012-015-0354-6. Review. — View Citation
Bienholz A, Wilde B, Kribben A. From the nephrologist's point of view: diversity of causes and clinical features of acute kidney injury. Clin Kidney J. 2015 Aug;8(4):405-14. doi: 10.1093/ckj/sfv043. Epub 2015 Jul 9. — View Citation
DeFronzo RA, Reeves WB, Awad AS. Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors. Nat Rev Nephrol. 2021 May;17(5):319-334. doi: 10.1038/s41581-021-00393-8. Epub 2021 Feb 5. Review. — View Citation
Mima A. Diabetic nephropathy: protective factors and a new therapeutic paradigm. J Diabetes Complications. 2013 Sep-Oct;27(5):526-30. doi: 10.1016/j.jdiacomp.2013.03.003. Epub 2013 Apr 22. Review. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Identify risk factors for Acute kidney injury in diabetic patients | Identify risk factors for Acute kidney injury in d iabetic patients | 2 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05563090 -
Investigating the Syndrome Differentiation of Diabetic and Pre-diabetic Using Digitalized TCM Diagnostic Tools
|
||
Recruiting |
NCT05333159 -
The Efficacy of SGLT-2 Inhibitor in Patients With CAD and DM Undergoing PCI.
|
||
Active, not recruiting |
NCT03119584 -
Efficacy of Linaclotide in Type II Diabetics With Chronic Constipation
|
Phase 4 | |
Completed |
NCT04409171 -
Glucose Metabolism After Partial Pancreatectomy
|
||
Recruiting |
NCT06060392 -
Effect of Oral Semaglutide on Liver Fat and Body Composition in Liver Transplant Recipients With Diabetes Mellitus
|
N/A | |
Completed |
NCT05144971 -
StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
|
||
Completed |
NCT03914183 -
Can mCPN Intervention Improve Injection Site Rotation
|
N/A | |
Completed |
NCT03781232 -
Non-invasive Glucose Measurement With Raman Technology in Patients With Type 1 and Type 2 Diabetes
|
N/A | |
Not yet recruiting |
NCT06150508 -
Randomized Controlled Trial of the Smart O2O Model Development for Chronic Diseases Management Through Digital Health
|
N/A | |
Completed |
NCT01252810 -
Safety Study of GE-145 320 mg I/mL Injection vs. Iopamidol 370 mg I/mL in Elderly Subjects Undergoing Coronary Procedure
|
Phase 2 | |
Active, not recruiting |
NCT04171557 -
Bicycling and Mortality Among Individuals With diabetesNutrition (EPIC)
|
||
Active, not recruiting |
NCT03155594 -
CGM to Aid Transition From Inpatient to Outpatient
|
N/A | |
Completed |
NCT04864327 -
Smoking Intervention Among Patients With Diabetes
|
N/A | |
Completed |
NCT04407182 -
Safety and Efficacy of Viusid and Asbrip in Hospitalized Patients Infected by SARS-Cov-2 With COVID-19
|
Phase 2 | |
Completed |
NCT05752591 -
Hypothalamic-pituitary Dysfunction in Diabetes
|
||
Completed |
NCT03159546 -
FreeStyle Libre Flash Glucose Monitoring System Accuracy
|
N/A | |
Completed |
NCT03953092 -
A Randomized, Double-blind, Placebo-controlled, Sequential Single and Multiple Ascending Doses of YG1699
|
Phase 1 | |
Not yet recruiting |
NCT06262854 -
Efficacy and Safety of Stimulan® for the Treatment of Diabetic Foot Osteomyelitis. The BIG D-FOOT Study
|
N/A | |
Completed |
NCT03934281 -
Study of the Value of Using a Honey Dressing Compared to the Use of a Standard Dressing on the Toe Amputation Wound in the Diabetic Patient
|
N/A | |
Not yet recruiting |
NCT03341026 -
Metronom Continuous Glucose Monitoring System
|
N/A |